Business Description
Thiogenesis Therapeutics Corp
NAICS : 325412
SIC : 3741
ISIN : CA88410L1022
Description
Thiogenesis Therapeutics Corp is a clinical-stage biotech company. The Company is developing thiol-active therapeutic compounds, that are prodrugs, used to treat unmet pediatric medical needs. TTI-0102, the Company's compound, was developed to address the obstacles facing previous thiol-based drugs, their short half-live, and side effects and it's initial applications are for mitochondrial disease, Rett syndrome, and pediatric NASH.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.98 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 4/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -80.3 | |||||
| 3-Year EPS without NRI Growth Rate | -80.3 | |||||
| 3-Year FCF Growth Rate | -69.6 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 32.86 | |||||
| 9-Day RSI | 40.11 | |||||
| 14-Day RSI | 43.01 | |||||
| 6-1 Month Momentum % | -11.27 | |||||
| 12-1 Month Momentum % | -13.7 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 40.13 | |||||
| Quick Ratio | 40.13 | |||||
| Cash Ratio | 39.12 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -16.9 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -88.36 | |||||
| ROA % | -78.85 | |||||
| ROIC % | -438900 | |||||
| ROCE % | -91.73 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 6.48 | |||||
| Price-to-Tangible-Book | 6.56 | |||||
| EV-to-EBIT | -6.49 | |||||
| EV-to-Forward-EBIT | -2.76 | |||||
| EV-to-EBITDA | -6.49 | |||||
| EV-to-Forward-EBITDA | -2.76 | |||||
| EV-to-FCF | -6.76 | |||||
| Price-to-Net-Current-Asset-Value | 6.56 | |||||
| Price-to-Net-Cash | 6.56 | |||||
| Earnings Yield (Greenblatt) % | -15.41 | |||||
| FCF Yield % | -15.02 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Thiogenesis Therapeutics Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil C$) | |||
| EPS (TTM) (C$) | -0.09 | ||
| Beta | 0 | ||
| Volatility % | 34.02 | ||
| 14-Day RSI | 43.01 | ||
| 14-Day ATR (C$) | 0.0229 | ||
| 20-Day SMA (C$) | 0.6205 | ||
| 12-1 Month Momentum % | -13.7 | ||
| 52-Week Range (C$) | 0.52 - 1.06 | ||
| Shares Outstanding (Mil) | 46.03 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Thiogenesis Therapeutics Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Thiogenesis Therapeutics Corp Stock Events
| Event | Date | Price(C$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Thiogenesis Therapeutics Corp Frequently Asked Questions
What is Thiogenesis Therapeutics Corp(TSXV:TTI)'s stock price today?
The current price of TSXV:TTI is C$0.59. The 52 week high of TSXV:TTI is C$1.06 and 52 week low is C$0.52.
When is next earnings date of Thiogenesis Therapeutics Corp(TSXV:TTI)?
The next earnings date of Thiogenesis Therapeutics Corp(TSXV:TTI) is .
Does Thiogenesis Therapeutics Corp(TSXV:TTI) pay dividends? If so, how much?
Thiogenesis Therapeutics Corp(TSXV:TTI) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers